
According to data from Benzinga Pro, during Q1, Mirati Therapeutics's (NASDAQ:MRTX) reported sales totaled $709.00 thousand. Despite a 5.63% increase in earnings, the company posted a loss of $188.39 million. Mirati Therapeutics collected $299.00 thousand in revenue during Q4, but reported earnings showed a $199.62 million loss.